Nektar Therapeutics (NASDAQ: NKTR) presented data from two Phase 2b studies of its drug rezpegaldesleukin at the 2026 American Academy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE